Equities

Shanghai Serum Bio-Technology Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Shanghai Serum Bio-Technology Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)26.55
  • Today's Change-0.48 / -1.78%
  • Shares traded1.71m
  • 1 Year change+47.99%
  • Beta0.9878
Data delayed at least 15 minutes, as of Feb 11 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Shanghai Serum Bio-Technology Co Ltd is a China-based company mainly engaged in the business of antisera and antitoxins. The Company is mainly engaged in the research, development, manufacturing and sales of preventive and therapeutic drugs as well as rapid diagnostic products for the field of biotoxins and biosafety. The Company's main products include anti-pit viper venom, anti-five-step snake venom, anti-bungi venom, anti-cobra venom, equine immunoglobulin and anti-rabies serum. The Company's products are mainly used for emergency snakebite treatment. The Company mainly conducts its businesses in the domestic market.

  • Revenue in CNY (TTM)196.76m
  • Net income in CNY45.55m
  • Incorporated1999
  • Employees326.00
  • Location
    Shanghai Serum Bio-Technology Co LtdNo. 1288, Huaqing Road, Qingpu DistrictSHANGHAI 201707ChinaCHN
  • Phone+86 2 164959122
  • Fax+86 2 164959122
  • Websitehttp://www.serum-china.com.cn/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Hainan Huluwa Pharmaceutical Grop Co Ltd902.48m-369.56m2.76bn2.10k--4.01--3.06-0.9236-0.92362.261.720.30551.741.60429,141.60-12.360.2178-22.130.373931.5354.80-40.470.32130.5566-6.970.6414700.10-21.261.60-2,629.23--21.75--
Zhejiang Shapuaisi Pharmaceutical Co Ltd475.19m-65.05m2.83bn1.33k--1.76--5.95-0.1796-0.17961.274.310.22362.3514.31357,822.00-3.08-2.12-3.66-2.4950.1155.38-13.78-7.330.8289-0.95060.1587---24.96-1.27-585.85--44.50--
Shanghai Serum Bio-Technology Co Ltd196.76m45.55m2.87bn326.0063.072.55--14.600.42090.42091.8210.400.17061.223.20603,567.303.957.644.047.8776.6878.9423.1530.0827.50--0.003577.342.510.714714.23-7.6018.77--
Hanshang Group Co Ltd1.04bn-7.75m2.96bn2.24k--1.77--2.86-0.0263-0.02633.515.660.29922.458.58463,254.10-0.50731.38-0.9112.5944.8061.66-1.703.790.3006-0.01940.30017.52-15.410.3108-123.83--4.52--
Novoprotein Scientific Inc147.33m-65.02m3.05bn566.00--1.46--20.72-0.9301-0.93012.1029.820.06640.75312.20260,302.10-2.934.36-3.024.5862.0174.11-44.1326.3524.75--0.022724.96-16.7328.80-523.69--166.98--
Ginwa Enterprise Group Inc550.44m78.32m3.10bn588.0038.521.96--5.640.21570.21571.544.240.28854.564.97936,120.604.040.8394.860.976276.3075.1414.002.831.84--0.056152.123.55-4.95273.9623.5628.320.00
Data as of Feb 11 2026. Currency figures normalised to Shanghai Serum Bio-Technology Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

1.20%Per cent of shares held by top holders
HolderShares% Held
Lion Fund Management Co., Ltd.as of 30 Jun 2025156.70k0.35%
China Asset Management Co., Ltd.as of 30 Jun 2025120.01k0.27%
E Fund Management Co., Ltd.as of 30 Jun 202590.45k0.20%
Penghua Fund Management Co., Ltd.as of 30 Jun 202534.45k0.08%
Fullgoal Fund Management Co., Ltd.as of 30 Jun 202528.63k0.07%
ICBC UBS Asset Management Co. Ltd.as of 30 Jun 202526.45k0.06%
Fortune & Royal Asset Management Co., Ltd.as of 30 Jun 202522.60k0.05%
CCB Principal Asset Management Co., Ltd.as of 30 Jun 202519.62k0.04%
Bosera Asset Management Co., Ltd.as of 30 Jun 202519.29k0.04%
New China Fund Management Co., Ltd.as of 30 Jun 202514.56k0.03%
More ▼
Data from 30 Jun 2025 - 05 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.